The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Positron Emission Tomography Using [18F]-Fluorodeoxy-d-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy
Abstract
PURPOSE: To determine whether [18 F]-fluorodeoxy-d-glucose ([18 F]-FDG) positron emission tomography (PET) can predict the pathologic response of primary and metastatic breast cancer to chemotherapy. PATIENTS AND METHODS: Thirty patients with noninflammatory, large (> 3 cm), or locally advanced breast cancers received eight doses of primary chemotherapy. Dynamic PET imaging was performed immediately before the first, second, and fifth doses and after the last dose of treatment. Primary tumors and involved axillary lymph nodes were identified, and the [18 F]-FDG uptake values were calculated (expressed as semiquantitative dose uptake ratio [DUR] and influx constant [K]). Pathologic response was determined after chemotherapy by evaluation of surgical resection specimens. RESULTS: Thirty-one primary breast lesions were identified. The mean pretreatment DUR values of the eight lesions that achieved a complete microscopic pathologic response were significantly (P = .037) higher than those from less responsive lesions. The mean reduction in DUR after the first pulse of chemotherapy was significantly greater in lesions that achieved a partial (P = .013), complete macroscopic (P = .003), or complete microscopic (P = .001) pathologic response. PET after a single pulse of chemotherapy was able to predict complete pathologic response with a sensitivity of 90% and a specificity of 74%. Eleven patients had pathologic evidence of lymph node metastases. Mean pretreatment DUR values in the metastatic lesions that responded did not differ significantly from those that failed to respond (P = .076). However, mean pretreatment K values were significantly higher in ultimately responsive cancers (P = .037). The mean change in DUR and K after the first pulse of chemotherapy was significantly greater in responding lesions (DUR, P = .038; K, P = .012). CONCLUSION: [18 F]-FDG PET imaging of primary and metastatic breast cancer after a single pulse of chemotherapy may be of value in the prediction of pathologic treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Phelps, M. E., Huang, S. C., Hoffman, E. J., Selin, C., Sokoloff, L., & Kuhl, D. E. (1979) · Annals of Neurology · doi:10.1002/ana.410060502 · Cited by 2,418
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
Carter, C. L., Allen, C., & Henson, D. E. (1989) · Cancer · doi:10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h · Cited by 2,288
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,801
Expression of Multidrug Resistance Gene in Human Cancers
Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.116 · Cited by 1,290
Quantitation in Positron Emission Computed Tomography: 1. Effect of Object Size
Hoffman, E. J., Huang, S.-C., & Phelps, M. E. (1979) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-197906000-00001 · Cited by 1,143
Fisher, B., Bauer, M., Wickerham, D. L., Redmond, C. K., Fisher, E. R., Cruz, A. B., Foster, R., Gardner, B., Lerner, H., Margolese, R., et al. (1983) · Cancer · doi:10.1002/1097-0142(19831101)52:9<1551::aid-cncr2820520902>3.0.co;2-3 · Cited by 1,034
The applications of PET in clinical oncology.
Strauss, L. G., & Conti, P. S. (1991) · PubMed · Cited by 844
Cited by
(2001) · PubMed · Cited by 943
Positron-Emission Tomography and Assessment of Cancer Therapy
Juweid, M. E., & Cheson, B. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050276 · Cited by 750
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy
Singletary, S. E. (2002) · The American Journal of Surgery · doi:10.1016/s0002-9610(02)01012-7 · Cited by 612
Bos, R., van der Hoeven, J. J. M., van der Wall, E., van der Groep, P., van Diest, P. J., Comans, E. F. I., Joshi, U., Semenza, G. L., Hoekstra, O. S., Lammertsma, A. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.379 · Cited by 591
Stroobants, S., Goeminne, J., Seegers, M., Dimitrijevic, S., Dupont, P., Nuyts, J., Martens, M., van den Borne, B., Cole, P., Sciot, R., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00073-x · Cited by 526
Bartel, T. B., Haessler, J., Brown, T. L. Y., Shaughnessy, J. D., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213280 · Cited by 518
Weber, W. A., Petersen, V., Schmidt, B., Tyndale-Hines, L., Link, T., Peschel, C., & Schwaiger, M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.004 · Cited by 493
Wieder, H. A., Brücher, B. L. D. M., Zimmermann, F., Becker, K., Lordick, F., Beer, A., Schwaiger, M., Fink, U., Siewert, J. R., Stein, H. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.122 · Cited by 454
Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer
Mortimer, J. E., Dehdashti, F., Siegel, B. A., Trinkaus, K., Katzenellenbogen, J. A., & Welch, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2797 · Cited by 410
Clinical Role of FDG PET in Evaluation of Cancer Patients
Kostakoglu, L., Agress, H., & Goldsmith, S. J. (2003) · RadioGraphics · doi:10.1148/rg.232025705 · Cited by 402
18F-FDG PET/CT Imaging In Oncology
Almuhaideb, A., Papathanasiou, N., & Bomanji, J. (2011) · Annals of Saudi Medicine · doi:10.4103/0256-4947.75771 · Cited by 388
Current Status of Breast MR Imaging Part 2. Clinical Applications
Kuhl, C. K. (2007) · Radiology · doi:10.1148/radiol.2443051661 · Cited by 377
Reske, S. N., & Kotzerke, J. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100626 · Cited by 365
Positron Emission Tomography Scanning: Current and Future Applications
Czernin, J., & Phelps, M. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104028 · Cited by 328
Ott, K., Fink, U., Becker, K., Stahl, A., Dittler, H.-J., Busch, R., Stein, H., Lordick, F., Link, T., Schwaiger, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.574 · Cited by 318
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Westerterp, M., Pruim, J., Oyen, W., Hoekstra, O., Paans, A., Visser, E., van Lanschot, J., Sloof, G., & Boellaard, R. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0224-1 · Cited by 294
Hawkins, D. S., Schuetze, S. M., Butrynski, J. E., Rajendran, J. G., Vernon, C. B., Conrad, E. U., & Eary, J. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7079 · Cited by 286
Krak, N. C., Boellaard, R., Hoekstra, O. S., Twisk, J. W. R., Hoekstra, C. J., & Lammertsma, A. A. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1566-1 · Cited by 283
Avril, N., Sassen, S., Schmalfeldt, B., Naehrig, J., Rutke, S., Weber, W. A., Werner, M., Graeff, H., Schwaiger, M., & Kuhn, W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.965 · Cited by 283
Performance of FDG PET/CT in the Clinical Management of Breast Cancer
Groheux, D., Espié, M., Giacchetti, S., & Hindié, E. (2013) · Radiology · doi:10.1148/radiol.12110853 · Cited by 271
Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
Costelloe, C. M., Chuang, H. H., Madewell, J. E., & Ueno, N. T. (2010) · Journal of Cancer · doi:10.7150/jca.1.80 · Cited by 270
FDG PET, PET/CT, and Breast Cancer Imaging
Rosen, E. L., Eubank, W. B., & Mankoff, D. A. (2007) · RadioGraphics · doi:10.1148/rg.27si075517 · Cited by 265
Ah-See, M.-L. W., Makris, A., Taylor, N. J., Harrison, M., Richman, P. I., Burcombe, R. J., Stirling, J. J., d'Arcy, J. A., Collins, D. J., Pittam, M. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4310 · Cited by 263
Hawkins, D. S., Rajendran, J. G., Conrad, E. U., Bruckner, J. D., & Eary, J. F. (2002) · Cancer · doi:10.1002/cncr.10599 · Cited by 257
PET/CT imaging in cancer: current applications and future directions
Farwell, M. D., Pryma, D. A., & Mankoff, D. A. (2014) · Cancer · doi:10.1002/cncr.28860 · Cited by 230
Metadata
- Authors
- Smith, I. C., Welch, A. E., Hutcheon, A. W., Miller, I. D., Payne, S., Chilcott, F., Waikar, S., Whitaker, T., Ah-See, A. K., Eremin, O., Heys, S. D., Gilbert, F. J., & Sharp, P. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-04-08
- Volume
- 18
- Issue
- 8
- Pages
- 1676-1688
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2177221443
- Cited by
- 406
- References
- 40
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.